Tempest Therapeutics to Acquire Factor Bioscience Dual-CAR T Programs in All-Stock Deal
Tempest Therapeutics, Inc. is set to acquire dual-CAR T programs from Factor Bioscience in an all-stock deal, adding TPST-2003 to its pipeline. The transaction, pending stockholder approval, is expected to close in early 2026. Post-acquisition, Matt Angel will become President and CEO, and Stephen Brady will be Chairman. The deal includes an investment commitment from Factor to support operations through mid-2027.
Tempest Therapeutics, Inc. has entered into definitive agreements to acquire certain dual-targeting chimeric antigen receptor (CAR)-T programs from Factor Bioscience Inc. and its affiliates in an all-stock transaction. The acquisition will add the first clinical-stage CD19/BCMA parallel structured dual-CAR T, referred to as TPST-2003, to Tempest’s pipeline, specifically targeting patients with extramedullary disease. The transaction, subject to stockholder approval and customary closing conditions, is anticipated to close in early 2026. Upon completion, Matt Angel, Ph.D., will become President and CEO, while Stephen Brady will assume the role of Chairman of the board of directors. Tempest expects the combined resources and an investment commitment from Factor to support operations through mid-2027, including key development and data milestones. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9578749-en) on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
